



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Mr B Smith
UNIVERSITY COLLEGE LONDON
MEDICAL RESEARCH COUNCIL CLINICAL TRIALS UNIT,
90 HIGH HOLBORN
LONDON
WC1V 6LJ
UNITED KINGDOM

09/01/2020

Dear Mr B Smith,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 20363/0380/001-0006
Eudract Number:	2017-002329-39
Product:	Durvalumab, Tremelimumab
Protocol number:	RE06
Substantial Amendment Code Number:	Code Number: 12 [Protocol Amendment] Version: v1.0 Date: 2019/11/28

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 05/12/2019.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**